Meta-analysis on the PARP-inhibitor olaparib reveals therapeutic efficacy in ovarian cancer independent of BRCA1/2 mutation status
作者: Ines Vasconcelos Oscar Gaspar
刊名: Advances in Modern Oncology Research, 2016, Vol.2 (2)
来源数据库: PiscoMed Publishing Pte. Ltd
DOI: 10.18282/amor.v2.i2.54
关键词: ovarian cancerPARP inhibitorsolaparibBRCA mutationBRCA1/2BRCAness
原始语种摘要: Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising drugs for ovarian cancer treatment. This study investigated clinical trials of PARP inhibitors, in order to obtain a more complete prognosis of ovarian cancer patients, which is usually dependent on their BRCA1/2 mutation status. The PubMed database was searched using the key terms “PARP inhibitor OR olaparib OR veliparib OR niraparib OR rucaparib OR (BMN 673) AND (ovarian cancer OR solid tumors)”, while narrowing the selection of the article type to “clinical trial” only. Women included in the study had been histologically diagnosed with recurrent high-grade serous ovarian-, fallopian tube- or primary peritoneal-carcinoma, regardless of the presence of BRCA germline mutation or platinum-sensitive disease...
全文获取路径: PiscoMed Publishing  (合作)

  • ovarian 卵巢的
  • serous 浆液的
  • platinum 
  • peritoneal 腹膜的
  • grade 品位
  • prognosis 预报
  • recurrence 循环
  • mutation 变种
  • narrowing 准备巷道掘进
  • cancer 癌症